BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
48.61
+1.64 (3.49%)
Sep 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.20 - 51.40
52 week 30.39 - 72.07
Open 46.32
Vol / Avg. 37,877.00/114,761.00
Mkt cap 321.60M
P/E 47.05
Div/yield     -
EPS 1.03
Shares 6.85M
Beta 0.99
Inst. own 59%
Sep 10, 2015
Biospecifics Technologies Corp at Rodman & Renshaw Global Investment Conference - 4:15PM EDT - Add to calendar
Sep 10, 2015
Biospecifics Technologies Corp at BioCentury NewsMakers in the Biotech Industry Conference - 8:30AM EDT - Add to calendar
Aug 11, 2015
Q2 2015 Biospecifics Technologies Corp Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Biospecifics Technologies Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 37.27% 33.00%
Operating margin 56.48% 49.72%
EBITD margin - 50.57%
Return on average assets 19.32% 17.12%
Return on average equity 19.87% 17.67%
Employees 5 -
CDP Score - -

Address

35 WILBUR ST
LYNBROOK, NY 11563-2358
United States - Map
+1-516-5937000 (Phone)
+1-516-5937039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioSpecifics Technologies Corp. is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that the Company may pursue, including human and canine lipoma. The Company generates revenue primarily from Auxilium pursuant to the Second Amended and Restated Development and License Agreement with Auxilium (Auxilium Agreement). Under the Auxilium Agreement, the Company receives license, sublicense income, royalties, milestones and mark-up on cost of goods sold payments related to the sale and approval of XIAFLEX.

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 80
Bio & Compensation  - Reuters
Jennifer M. Chao Independent Director
Age: 45
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 77
Bio & Compensation  - Reuters